drugset / Trial / NCT03268902

Early Life Interventions for Childhood Growth and Development In Tanzania

NCT03268902 ↗

RandomizedFactorialQuadruple-blindTreatment

Summary

This study aims to assess growth and cognitive effects of treatment with azithromycin and nitazoxanide and/or nicotinamide (vitamin B3) supplementation nicotinamide.

Timeline

Start
2017-09-05
Primary completion
2020-02-28
Completion
2020-03-26

Outcome

Missed primary endpoint

paper antimicrobial: -2.05 CI -2.13, -1.96, placebo: -2.05 CI -2.14, -1.97; mean difference: 0.01 CI -0.13, 0.11, p = 0.91 PMID 34582462 ↗

paper nicotinamide: -2.06 CI -2.13, -1.95, placebo: -2.04 CI -2.14, -1.98, mean difference 0.03 CI -0.15, 0.09, p = 0.66 PMID 34582462 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 20 mg/kg Oral
Subject Nicotinamide Other / unclassified 100 mg Oral
Subject Nicotinamide Other / unclassified 250 mg Oral
Subject Nitazoxanide Other / unclassified 100 mg Oral